Considering the complex pathophysiological mechanisms of diseases such as bronchiectasis, combination application strategies of DPP1 inhibitors with other therapeutic drugs merit in-depth study (Chalmers et al., 2019). This evidence concerns the gene CTSC and bronchiectasis.